Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
I• Inclusion~* 18-90 years old~* Male or female~* Age of fracture greater than or equal to 6 weeks~* Single Level Vertebral Compression Fracture~* Vertebral compression fracture Thoraic-9 to Lumbar-5~* NRS \>6/10~  • Exclusion~* \<18 or \>90 yo~* Uncorrectable Coagulopathy~* Multiple Level Vertebral Compression Fractures~* Surgery within 60 days of presentation~* Active infection~* Rhuematologic disease~* Significant neurologic deficit~* Radicular pain~* Chronic low back pain in last year~* Inability to give consent~* Cognitive impairment~* Patients with Ongoing Litigation or Worker's Compensation Cases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks.
- Treatment Group (Type: ACTIVE_COMPARATOR): The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
- Crossover Group (Type: ACTIVE_COMPARATOR): This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).